IP Library Granted Patent US 10,583,208
Granted Patent B2
US 10,583,208 · App. 16/264,176 · Granted Mar 10, 2020

Methods for making ultrasound contrast agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,208
App. No.
16/264,176
Granted
Mar 10, 2020
Kind
B2
Abstract

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Claims (24)

1. A method of ultrasound contrast imaging a subject comprising

(a) combining an aqueous solvent with a phospholipid solution to form a phospholipid suspension, and activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE, and propylene glycol, the MPEG5000-DPPE selected as having a combined calcium and magnesium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a combined calcium and magnesium concentration of less than 0.7 ppm,

(b) administering the lipid-encapsulated gas microspheres to a subject, and

(c) obtaining an ultrasound image of the subject.

2. The method of claim 1 , wherein DPPA, DPPC and MPEG5000-DPPE are present in molar percentages of 5-15%, 77-90% and 5-15%, respectively.

3. The method of claim 1 , wherein DPPA, DPPC and MPEG5000-DPPE are present in a % mole ratio of about 10 to 82 to 8.

4. The method of claim 1 , wherein the perfluorocarbon gas is perfluoropropane gas.

5. The method of claim 1 , wherein the combined calcium and magnesium concentration of DPPA is less than 780 ppm, the combined calcium and magnesium concentration of DPPC is less than 90 ppm, and the combined calcium and magnesium concentration of propylene glycol is less than 0.7 ppm.

6. The method of claim 1 , wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE and propylene glycol, and the aqueous solvent comprises water, propylene glycol and glycerol, and wherein the phospholipid suspension comprises DPPA, DPPC, MPEG5000-DPPE, propylene glycol, water and glycerol.

7. The method of claim 6 , wherein water, glycerol and propylene glycol are present in a ratio of about 8:1:1 in the phospholipid suspension.

8. The method of claim 6 , wherein the aqueous solvent further comprises one or more salts.

9. The method of claim 6 , wherein the aqueous solvent further comprises one or more buffers.

10. A method of ultrasound contrast imaging a subject comprising

(a) combining an aqueous solvent with a phospholipid solution to form a phospholipid suspension, and activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid suspension is formed under a methanol and toluene free condition and a methyl-t-butyl ether free condition, the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE, and propylene glycol, the MPEG5000-DPPE having a combined calcium and magnesium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a combined calcium and magnesium concentration of less than 0.7 ppm,

(b) administering the lipid-encapsulated gas microspheres to a subject, and

(c) obtaining an ultrasound image of the subject.

11. The method of claim 10 , wherein DPPA, DPPC and MPEG5000-DPPE are present in molar percentages of about 5-15%, 77-90% and 5-15%, respectively.

12. The method of claim 10 , wherein DPPA, DPPC and MPEG5000-DPPE are present in a % mole ratio of about 10 to 82 to 8.

13. The method of claim 10 , wherein the perfluorocarbon gas is perfluoropropane gas.

14. The method of claim 10 , wherein the combined calcium and magnesium concentration of DPPA is less than 780 ppm, the combined calcium and magnesium concentration of DPPC is less than 90 ppm, and the combined calcium and magnesium concentration of propylene glycol is less than 0.7 ppm.

15. The method of claim 10 , wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE and propylene glycol, and the aqueous solvent comprises water, propylene glycol and glycerol, and wherein the phospholipid suspension comprises DPPA, DPPC, MPEG5000-DPPE, propylene glycol, water and glycerol.

16. The method of claim 15 , wherein water, glycerol and propylene glycol are present in a ratio of about 8:1:1 in the phospholipid suspension.

17. The method of claim 15 , wherein the aqueous solvent further comprises one or more salts.

18. The method of claim 15 , wherein the aqueous solvent further comprises one or more buffers.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2019
From: ROBINSON, SIMON P.; SIEGLER, ROBERT W.; NGUYEN, NHUNG TUYET; ONTHANK, DAVID C.; ANKLEKAR, TARAKESHWAR VISHWANATH; VAN KIRK, CHARLES CHESTER
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049581/0335 →